stockrow
Friday 6 November 2026
Export COAG’s income statement to Excel — free account
Hemab Therapeutics Holdings, Inc.
COAG Healthcare Biotechnology
48.60
3.03
+6.65%
Follow COAG
Alert me
| Older periods | Jun '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+1 more quarter Free account |
— | 18.03 | 12.85 | 35.85 |
Net Debt/EBITDA |
0.00 | 0.00 | 6.95 | 17.59 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
— | — | — | 0.00 | |
Operating CF/Net income |
1.26 | — | 0.95 | 0.94 | |
Capex/Depreciation |
0.00 | — | (1.53) | (0.31) | |
Research and Development Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 0.00% | |
Free Cash Flow per Share |
(16.21) | — | (22.93) | (0.75) | |
Cash per Share |
0.00 | 0.00 | 172.87 | 15.19 | |
Shareholders Equity per Share |
0.00 | 0.00 | (209.96) | 15.09 | |
Interest Debt per Share |
0.00 | — | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | (209.96) | 15.09 | |
Free Cash Flow |
(15.33) | — | (21.70) | (22.66) | |
Working Capital |
— | 181.87 | 156.24 | 451.05 | |
Capital Expenditures |
0.00 | — | (0.11) | (0.02) | |
Net Current Asset Value |
0.00 | (178.87) | (204.44) | 450.49 | |
| Other line items | |||||
Quick Ratio |
— | 17.37 | 12.40 | 35.34 | |
Revenue per Share |
0.00 | — | 0.00 | 0.00 | |
Operating CF per Share |
(16.21) | — | (22.82) | (0.75) | |
Capex per Share |
0.00 | — | (0.12) | 0.00 | |
Average Assets |
— | — | — | 233.89 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 |
Columns are period end dates